GemPharmatech (SH:688046) Xin Lang Cai Jing·2025-10-10 01:42Core Insights - Jiangsu Jicui Pharmaceutical Technology Co., Ltd. (药康生物) experienced a stock decline of 2.33% on October 9, with a trading volume of 43.15 million yuan [1] - The company reported a financing buy-in of 6.07 million yuan and a net financing buy of 132,300 yuan on the same day, indicating low financing levels compared to the past year [1] - As of June 30, 2025, the company achieved a revenue of 375 million yuan, a year-on-year increase of 10.11%, while the net profit attributable to shareholders decreased by 7.12% to 70.91 million yuan [2] Financing and Stock Performance - On October 9, the total financing and securities lending balance for Jiangsu Jicui was 69.77 million yuan, with a financing balance of 69.54 million yuan, representing 0.96% of the circulating market value [1] - The company’s financing balance is below the 50th percentile level over the past year, indicating a relatively low financing position [1] - The securities lending data showed a repayment of 600 shares and a sale of 200 shares, with a remaining securities lending balance of 1,320 shares, which is above the 60th percentile level over the past year [1] Shareholder and Dividend Information - As of June 30, 2025, the number of shareholders increased by 23.68% to 7,213, with an average of 56,841 circulating shares per person, up 62.56% [2] - The company has distributed a total of 139 million yuan in dividends since its A-share listing [3] - Notable changes in institutional holdings include a decrease in shares held by major shareholders, with new entries among the top ten shareholders [3]